Immune Responses Following Locoregional Treatment for Hepatocellular Carcinoma: Possible Roles of Adjuvant Immunotherapy
Hepatocellular carcinoma (HCC) is a common cause of cancer-related deaths worldwide. Unlike other types of cancer, HCC can be treated with locoregional treatments (LRTs) such as radiofrequency ablation (RFA) or transarterial chemoembolization (TACE). However, recurrences following LRTs are common, a...
Saved in:
Main Authors: | Ji-Won Han (Author), Seung-Kew Yoon (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2021-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Statin therapy: a potential adjuvant to immunotherapies in hepatocellular carcinoma
by: Jiao Wang, et al.
Published: (2024) -
Prognostic significance of viable tumor size measurement in hepatocellular carcinomas after preoperative locoregional treatment
by: Yoon Jung Hwang, et al.
Published: (2021) -
Advances in immune checkpoint inhibitors for hepatocellular carcinoma
by: Ji Won Han, et al.
Published: (2021) -
Amphiregulin as a novel diagnostic and prognostic biomarker of hepatocellular carcinoma before and after locoregional treatment
by: Amira Isaac, et al.
Published: (2021) -
Immunotherapy in Hepatocellular Carcinoma
Published: (2023)